Because there are no available molecular markers for pulmonary mucormycosis (PM), which has low culture sensitivity, early diagnosis and treatment rely heavily on imaging modes such as computed tomography (CT). However, there are limited data comparing CT findings for PM with those for invasive pulmonary aspergillosis (IPA). Adult patients who met the modified criteria for proven and probable PM (over an 11year period) and IPA (over a 6-year period, owing to the availability of the galactomannan assay) according to the modified European Organization for Research and Treatment of Cancer/Mycosis Study Group definitions were retrospectively enrolled. IPA cases were selected at a 1 : 4 (PM/IPA) ratio. Thoracic CT scans were reviewed by two experienced radiologists blinded to the patients' demographics and clinical outcomes. A total of 24 patients with PM, including 20 (83%) with proven PM and four (17%) with probable PM, and 96 patients with IPA, including 12 (13%) with proven IPA and 84 (87%) with probable IPA, were eventually analysed. The reverse halo sign was more common in patients with PM (54%) than in those with IPA (6%, p < 0.001), whereas some airway-invasive features, such as clusters of centrilobular nodules, peribronchial consolidations, and bronchial wall thickening, were more common in patients with IPA (IPA 52% vs. PM 29%, p 0.04; IPA 49% vs. PM 21%, p 0.01; IPA 34% vs. PM 4%, p 0.003, respectively). The reverse halo sign was more common, and airway-invasive features were less common, in patients with PM than in those with IPA. These findings may help physicians to initiate Zygomycetes-active antifungal treatment earlier.
Introduction
Recently, chest computed tomography (CT) has given us important clues for the clinical suspicion and early treatment of invasive mould pneumonia in immunocompromised patients [1, 2] . The CT findings of invasive pulmonary aspergillosis (IPA) in immunocompromised patients have been relatively well described [3, 4] . However, there are limited data comparing CT findings for pulmonary mucormycosis (PM) with those for IPA.
To our knowledge, there has been only one report comparing clinical and radiological findings in PM and IPA [5] , and it demonstrated that multiple (ten or more nodules) and pleural effusion were independent predictors of PM [5] . A recent study reported that the reverse halo sign (RHS) was present in 15 (94%) of 16 patients with PM during the first week of the disease, and the authors proposed that the RHS could be a sensitive sign for PM, especially early in the disease [6] . However, whether the RHS is specific for PM can only be discovered by comparing the radiological findings for IPA with those for PM. We therefore compared the findings for PM and for IPA.
Materials and methods

Study population
This study was performed at the Asan Medical Centre, a 2700bed tertiary-care teaching hospital in Seoul, South Korea. The medical records of adult patients (aged 16 years) who met the criteria for proven or probable PM were retrospectively reviewed from January 2003 to December 2013. In addition, all patients who met the criteria for proven or probable IPA from January 2008 to December 2013 were retrospectively reviewed. Because the galactomannan (GM) assay became available in our hospital in 2008, IPA cases between January 2008 and December 2013 were enrolled. We excluded patients with PM or IPA and co-infection with other pathogens.
Definitions
Proven PM was defined by histological evidence of tissue invasion consisting of non-septated, right-angle branching filamentous fungi plus recovery of Mucorale species by culture of specimens from pulmonary tissue or positivity for immunohistochemical staining with anti-Rhizopus arrhizus monoclonal antibody (LSBio, Seattle, WA, USA). Probable PM was defined as the presence of host factors together with one or more clinical indications, such as dense, well-circumscribed lesions with or without a halo sign, and an air-crescent sign or cavity on CT, and mycological evidence of Zygomycetes in sputum or bronchoalveolar lavage (BAL) fluid culture, as defined by the revised criteria of the European Organization for Research and Treatment of Cancer/Mycosis Study Group [7] .
Proven IPA was defined by histological evidence of tissue invasion consisting of septated, acutely branching filamentous fungi plus recovery of Aspergillus species by culture of pulmonary tissue, or positivity for immunohistochemical staining with anti-Aspergillus monoclonal antibody (LSBio). Probable IPA was defined as the presence of host factors together with one or more clinical indications such as dense, wellcircumscribed lesions with or without a halo sign, and an air-crescent sign or cavity on CT, and mycological evidence of fungal infection (by culture or cytological analysis of BAL fluid for Aspergillus species, or GM assay of serum or BAL fluid) as, defined by the revised criteria of the European Organization for Research and Treatment of Cancer/Mycosis Study Group [7, 8] .
IPA cases were selected in a 4 : 1 ratio to PM cases. The selection was performed in the following order (diagnostic certainty order) to achieve the calculated sample size: (a) all patients with proven IPA; (b) all patients with probable IPA whose sputa or BAL fluids yielded Aspergillus species; and (c) randomly selected patients with probable IPA, with negative culture of sputa or BAL fluid.
CT evaluation
CT evaluation was performed by two radiologists who were unaware of patients' characteristics and clinical outcomes. The final decision was made by consensus after discussion.
We used a glossary of CT imaging definitions to categorize pulmonary lesions [9] . Radiological patterns of IPA were classified, on the basis of previous studies, as: (a) angio-invasive pneumonia, (b) airway-invasive pneumonia, and (c) necrotizing pneumonia [10, 11] . The following radiological patterns were considered to be angio-invasive: macronodules (Figs S1A and S4D), mass-shaped consolidations ( Fig S4A-C) , infarct-shaped onsolidations ( Fig S1A-C) , or halo signs ( Fig S4A,B) . The following radiological patterns were considered to be airway invasive: clusters of centrilobular nodules ( Fig S2A-D) , peribronchial consolidations ( Fig S2A-D) , ground-glass opacities ( Fig S2D) , and smooth bronchial wall thickening ( Fig S2A-C) . The following radiological patterns were considered to indicate necrotizing pneumonia: air-crescent signs (not shown), cavitary lesions (Figs S1C and S2B), internal low attenuation as compared with muscle ( Fig S3A,B) , the RHS ( Fig S4A-C) or the bird's nest sign (BNS) ( Fig S3B,C) .
A typical RHS ( Fig S4A-C) was defined as a mass-like lesion with a central ground-glass opacity or central lucency, or surrounded by a ring of consolidation, regardless of size [12] . A BNS ( Fig S3B,C) was defined as a mass-like lesion, intermingled with central necrotic low attenuation, small cavities, and ground-glass opacities surrounded by a ring of consolidations >3 cm in long diameter [13] . The RHS and BNS have been used without distinction in previous studies [6, 13] . We used RHS as a combined term for typical RHS (with a more organized pneumonia-like appearance) and BNS (with a more necrosislike appearance), because RHS is the preferred term according to the Fleischner Society [9] .
We investigated and compared the evolution of thoracic CT findings in PM and IPA according to stage, with the stage divided into three periods (days 0-5, days 6-14, and day 15 onwards). Day 0 of the disease was defined as the day of the first clinical symptoms and signs.
Statistical analysis
Categorical variables were compared by use of the χ 2 -test or Fisher's exact test, as appropriate, and continuous variables were compared by the use of Student's t-test and the Mann-Whitney U-test, as appropriate. All tests of significance were two-tailed, and a p-value of <0.05 was considered to indicate statistical significance. Calculations were performed with SPSS for Windows, version 21K (SPSS, Chicago, IL, USA).
Results
Patient characteristics
During the study period, a total of 24 patients, consisting of 20 patients with proven PM and four with probable PM, were enrolled ( Fig. 1 ). There were 234 patients, comprising 12 with proven IPA and 222 with probable IPA, during the study period ( Fig. 1 ). Among the 222 patients with probable IPA, 65 (29%) yielded positive Aspergillus cultures from non-sterile specimens. Therefore, the 12 patients with proven IPA and the 65 patients with probable IPA whose sputa or BAL fluid yielded Aspergillus species were included in the final analysis. Of the remaining 157 patients with probable IPA who yielded negative Aspergillus cultures but positive GM assay results, 19 patients selected at random were included in the final analysis. Thus, 96 patients, 12 (13%) with confirmed IPA and 84 (87%) with probable IPA, were finally analysed.
The baseline characteristics, treatments and outcomes of all of the patients are shown in Table 1 . Almost half of the patients with PM or IPA had haematological malignancies. The median time between the first clinical signs and the first CT scan was similar in the PM and IPA patients (PM, 6 days vs. IPA, 7 days; p 0.75). Interestingly, the serum GM assay gave positive results in 22% of the patients with PM and in 77% of those with IPA (p < 0.001). The detailed clinical and mycological results of patients with positive serum or BAL GM assay are shown in Table S1 .
CT features of PM and IPA All but five patients underwent CT, based on the clinical suspicion. We compared the CT findings between the 24 patients with PM and the 96 patients with IPA ( Table 2 ). Typical clinical cases and CT findings of the patients with IPA and PM are shown in Figs S1 and S2, and Figs S3 and S4, respectively. The RHS was more common in patients with PM than in those with IPA (p 0.001) (Figs S3 and S4). Centrilobular nodules (<10 mm, clustered) (p 0.04), peribronchial consolidations (p 0.01) and smooth bronchial wall thickening (p 0.003)-typical airwayinvasive forms-were more common in patients with IPA than in patients with PM ( Fig S2) . Solitary lesions were more common in patients with PM than in patients with IPA (p 0.03).
In a subgroup analysis stratified by the 48 patients with neutropenic status, mass-shaped consolidations (p 0.01) and the RHS (p 0.005) were more common in neutropenic patients with PM than in those with IPA (Table S2 ). Among the 72 nonneutropenic patients, airway-invasive forms, including clusters of centrilobular nodules (p 0.03), peribronchial consolidation (p 0.01), and bronchial wall thickening (p 0.005), were more common in patients with IPA than patients with PM, whereas the RHS was more common in patients with PM (p < 0.001) ( Table S3 ). The RHS was more frequent in neutropenic patients with PM (80% (4/5)) than in non-neutropenic patients with PM (47% (9/ 19)), but the difference was not statistically significant (p 0.19).
Evolution of CT findings in PM and IPA
The evolution of the CT findings in PM and IPA is shown in Fig. 2 . Between day 0 and day 5, nine patients with PM and 41 patients with IPA underwent CT scanning. The RHS was seen in four of the former, and in three of 39 patients with IPA (p 0.02). Almost half of the patients with IPA showed bronchial wall thickening, as compared with none of the patients with PM. Macronodules, mass-like consolidations and the RHS were common features in both groups at this stage. From day 6 to day 14, nine patients with PM and 36 patients with IPA underwent CT scanning. The RHS was observed in seven of the patients with PM and in one patient with IPA (p < 0.001). The RHS only appeared within 5 days from symptom onset in 
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Clinical Microbiology and Infection, Volume 21 Number 7, July 2015 approximately half of the patients, but were observed within 14 days from symptom onset in~80% of the patients (Fig. 2C) . Peribronchial consolidations and air-crescent signs were also evident (p 0.02, respectively). After day 15, five of six patients with PM showed mass-like consolidations (p 0.06).
Discussion
The low culture-positive rate of PM and the lack of biological markers for PM make it difficult to suspect PM early and provide specific therapy for it; in addition, early clinical suspicion of IPA is not sufficiently convincing to permit the administration of voriconazole therapy, as the GM assay has insufficient sensitivity to rule out IPA and not enough specificity to rule in IPA. Here, we found that the RHS was specific for PM, especially within 2 weeks from symptom onset, but it was not sensitive enough to rule out PM, even early in the disease. However we also found that certain types of airway-invasive structure, such as centrilobular nodules, peribronchial consolidations, and bronchial wall thickening, were more common in patients with IPA than in those with PM. Therefore, our findings ANC, absolute neutrophil count; BAL, bronchoalveolar lavage; CT, computed tomography; IQR, interquartile range. a Corticosteroid use is defined as the use of corticosteroids at a mean minimum dose of 0.3 mg/kg/day of prednisolone equivalent for >3 weeks. b Treatment with other recognized T-cell immunosuppressants, such as cyclosporine, tumour necrosis factor-α blockers, or specific monoclonal antibodies (such as alemtuzumab) during the past 90 days. c Gastrointestinal tract involvement was found in two patients, a concurrent brain lesion was found in one patient, and multiple metastatic lesions (brain, thyroid, gastrointestinal tract, and heart) were found in one patient. d Concurrent skin lesions were found in two patients, multiple metastatic lesions (skin and brain) were found in one patient, and hepatic and hepatosplenic lesions were found in the remaining two patients, respectively. e This analysis was limited to transplant recipients. f The 20 patients with proven PM showed histomorphology compatible with mucormycosis, and had positive results with the anti-Rhizopus arrhizus antibody but negative results with the anti-Aspergillus antibody. Of the 20 patients with proven PM, one was positive for Absidia species from pulmonary tissue culture, and two were positive for Rhizopus species from maxillary sinus and sputum culture, respectively. g Of the 12 patients with proven IPA, 11 had available results of immunohistochemical staining with anti-Aspergillus antibody, and ten showed histomorphology compatible with aspergillosis and had positive results with the anti-Aspergillus antibody but negative results with the anti-Rhizopus arrhizus antibody. The remaining two patients with proven IPA had histomorphology compatible with aspergillosis, and yielded a positive Aspergillus culture from a sterile specimen. h Of the four patients with probable PM, one was positive for Cunninghamella species from sputum culture, two were positive for Rhizopus species from sputum and BAL culture, and one was positive for Mucor species from nasopharyngeal aspirate culture.
should help clinicians to suspect and differentiate PM from IPA, and, where appropriate, initiate Zygomycetes-active antifungal treatment early. Several retrospective studies have shown that the RHS is present in PM. Vogl et al. reported that five of nine (56%) patients with PM had the BNS [13] . They first described the BNS in patients with PM, whose CT images were slightly different from the typical RHS as seen from our perspective. Wahba et al. observed the RHS in eight (22%) of 37 patients with invasive mould infections, including seven with mucormycosis and one with aspergillosis [14] . Recently, Legouge et al. reported the RHS in 15 (94%) of 16 leukaemic patients with mucormycosis during the first week of the disease [6] . In addition, the authors could not infer the diagnostic performance of the RHS for the diagnosis of PM without comparing the radiological findings for IPA with those for PM [6] . We clearly showed that the RHS is specific for PM, but is not a very sensitive marker for it. The reason for the differences in sensitivity in the various studies is not clear. One possible explanation could be that the CT scans were performed at different stages of the disease. The previous study proposed that the RHS appeared within 5 days of symptom onset, and disappeared subsequently. However, we found that the RHS only appeared within 5 days from symptom onset in one-quarter of the patients, but was observed within 14 days from symptom onset in~80% of patients. However, only 38% (9/24) of patients underwent a CT scan within 5 days from symptom onset in this study, as compared with 100% (16/16) of patients in the study of Legouge et al. [6] . In fact, the median time from symptom onset to the first CT scan in patients with PM was 6 days in the present study, as compared with 1 day in the study of Legouge et al. [6] . Therefore, further studies on this are needed. Another possible explanation could be differences in host factors. For example, the previous study [6] included 15 neutropenic patients among the 16 patients with PM, whereas the current study included only five neutropenic patients among the 24 patients with PM. It is therefore possible that the RHS might be more frequent in the neutropenic state. In fact, the RHS was seen in four of five neutropenic patients in our study within 11 days from onset of symptoms. The remaining patient only underwent a CT scan 19 days after symptom onset. Taken together, these findings suggest that, until further well-designed studies are available, it would be better not to exclude PM when the RHS is absent, and that anti-Zygomycetes agents should be administered promptly in the presence of the RHS, as the RHS is uncommon in IPA.
As the pathophysiological mechanism of the RHS in fungal pneumonia is not known, it is difficult to explain why it is more frequent in PM than in IPA. Okubo et al. showed that the centre of the dense nodule in IPA consisted of an exudate in the alveolar air space, whereas in PM the alveolar air space was not filled with exudate [15] . The authors proposed that the extensive penetration of Aspergillus into the lung was able to induce plasma exudation, whereas Mucor penetrates through the septal wall from the lumen of a capillary or the small vasculature [15] . Thus, a difference in the intensity of penetration and angio-invasiveness between Mucor and Aspergillus could underlie the difference in the RHS between PM and IPA. Further radiopathological correlation studies are needed.
In a previous study, we showed that airway-invasive forms such as small-airway lesions and peribronchial consolidations were frequent in non-neutropenic patients with IPA [4] . Therefore, the frequent finding of airway invasiveness in IPA was not unexpected, because approximately half of the patients with IPA did not have neutropenia. However, it is interesting that a certain type of airway invasiveness was less frequent in PM than in IPA. This could explain why Mucorales infections generally occur earlier and are more angio-invasive than Aspergillus infections [6] . This is also supported by our finding that halo signs tend to be more frequent in PM than in IPA. Therefore, we believe that a combination of the presence of the RHS and an absence of airway invasiveness on CT images could differentiate PM from IPA. This study has several limitations. First, six (29%) of 21 patients with PM whose GM assay results were available yielded positive serum or BAL GM assay results. Hence, some might argue that the patients with PM who had positive GM assay results could be misclassified. However, three of six patients whose GM assays gave positive results also yielded Rhizopus species and Mucor species from sterile culture or non-sterile culture (Table S1 ). The possible explanations for positive GM assay results in patients with proven PM could be the falsepositive GM assay results associated with use of antibiotics such as piperacillin-tazobactam, blood products, or Plasma-Lyte [16] [17] [18] , the cross-reaction between the mucormycosis antigen and GM [19] , and the colonization of Aspergillus in the damaged bronchi in patients with mucormycosis without overt tissue invasion [20] . Therefore, cautious interpretation of positive GM results is needed when a patient shows CT findings compatible with fungal pneumonia without other mycological evidence. The second limitation was the difference in confirmed cases between PM and IPA. PM has no biomarker such as the GM assay used for probable IPA, so the proportion of probable PM cases was inevitably lower than that of probable IPA cases. Therefore, many cases of PM with culture-negative cases were not included in this study, and the patients who could tolerate invasive work-up and survived until the invasive work-up for PM were enrolled in this study. This type of selection bias could be a partial explanation for the lower 30-day mortality in patients with PM than in those with IPA (Table 1 ). In this context, the present study design would not be suitable for the comparison of outcome between PM and IPA. However, this bias could not alter our main findings related to CT scans in this study. It is worth noting that we clearly demonstrated that the RHS was a specific sign for differentiating PM from IPA, by showing that the RHS was observed in <5% of the patients with IPA, despite the heterogeneity of the patients and the retrospective nature. Third, most of the patients with proven mucormycosis and proven aspergillosis showed histomorphology compatible with mucormycosis and aspergillosis, with positive immunohistochemical stains, in the absence of positive culture from sterile specimens. Some authors have therefore questioned the diagnostic specificities of these commercially available monoclonal antibodies for immunohistochemical staining. When we evaluated the diagnostic performance for mucormycosis and aspergillosis immunohistochemical staining in patients with sterile culture-proven mucormycosis (n = 7) and aspergillosis (n = 8) cases, the specificities for mucormycosis and aspergillosis immunohistochemical staining were 100% and 100%, respectively (unpublished data). Therefore, we believe that the commercially available monoclonal antibodies for immunohistochemical staining are useful in distinguishing between mucormycosis and aspergillosis, given that fungal culture has low sensitivity. Fourth, recent studies have shown that the vascular occlusion sign is a sensitive and specific sign of invasive mould pneumonia [21] [22] [23] . The fact that >60% (74/ 120) of patients in our study had CT performed without contrast enhancement could have affected the diagnostic accuracy. However, the routine performance of CT angiography in patients suspected of having invasive mould infection is a controversial issue, owing to concerns about contrast-induced acute renal failure. Further studies in this area are needed.
In conclusion, the RHS is a more frequent feature of PM than of IPA; conversely, the airway-invasive form is a less common feature of PM than of IPA. Together, these findings may help physicians to pre-emptively initiate Zygomycetes-active antifungal treatment.
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